Associated Papers
Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report.
Chen J et al.
Translational Cancer Research, 2022
NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report.
Wang H et al.
Frontiers in Oncology, 2022
Select a paper to view details